Essity Slashed to Underweight by JPMorgan

Lead

On April 20, 2026 JPMorgan cut its rating on hygiene-products group Essity to "underweight", citing sharply higher pulp and energy costs that the bank says will materially squeeze margins and cash flow (source: Investing.com, Apr 20, 2026). The downgrade crystallises investor concern that input-cost inflation has moved beyond a temporary shock — JPMorgan's note flagged both pulp and power as persistent headwinds rather than transitory spikes. The move comes as pulp benchmark indexes and European wholesale power contracts have shown elevated readings through Q1 2026; JPMorgan's judgement is that these cost pressures will weigh on Essity's 2026 operating profit trajectory. Market participants will watch revisions to company guidance and analyst forecasts closely: the downgrade is a risk signal for earnings revisions and could amplify share volatility in a tightly priced consumer staples sector.

Context

Essity is a leading global producer of hygiene and health products, operating across tissue, professional hygiene and consumer health segments. The company's cost base is unusually exposed to market pulp and energy — pulp is the principal raw material for its tissue business and energy is critical to production and logistics — which makes movements in commodity and power markets material to near-term margins. JPMorgan's downgrade on April 20, 2026 follows a period in which independent price series for softwood pulp (e.g., FOEX CNI pulp index) and European power curves recorded higher readings compared with a year earlier, pressuring gross margins for manufacturers across the supply chain (source: FOEX; Nord Pool indices, Q1 2026). The downgrade therefore shifts the investor debate from "will input inflation ease?" to "how long and how much will it compress margins?" for Essity and peers.

The timing of the note also intersects with calendar events that matter to consensus forecasts: most sell-side teams were completing Q2 updates and modelling FY26 assumptions in April. A rating change from a major house such as JPMorgan can trigger reappraisals of consensus operating profit and free cash flow (FCF) forecasts, and prompt portfolio managers to reweight exposures in consumer staples. Historically, Essity has been priced for defensive stability — a characteristic that can be re-rated quickly if the margin base proves more cyclical than investors expect. That dynamics matters because consumer staples multiples compressed earlier in 2026 relative to the consumer discretionary cohort, and any upward re-rating of input-cost risk would widen relative performance dispersion.

Data Deep Dive

Three specific datapoints frame the revision and explain JPMorgan's reasoning. First, the downgrade was published on April 20, 2026 (source: Investing.com). Second, pulp indices measured by FOEX showed a material year-over-year increase through March 2026 — FOEX reported pulp index levels roughly 20-30% higher than the comparable period in 2025, a sizeable swing for high-volume tissue producers (source: FOEX CNI index, March 2026). Third, European wholesale power contracts for calendar 2026 traded materially above 2024 averages in Q1, with some baseload curves up by multiples in specific countries where gas-to-power spreads widened (source: Nord Pool & regional power exchanges, Q1 2026). These inputs combine to lift cash costs at a rate that, JPMorgan argues, will not be fully mitigated by near-term pricing actions or cost pass-through.

From a company-financials angle, the critical mechanics are straightforward. Tissue makers typically source pulp either on index-linked contracts or via shorter-term negotiated purchases; a 20-30% rise in pulp cost translates into a non-trivial percentage point hit to gross margin because raw materials represent a high share of cost of goods sold. Energy costs operate similarly, with manufacturing intensity amplifying the impact in energy-intensive lines. If Essity is unable to pass through the full magnitude of these increases to end-customers — given competitive dynamics and retailer price sensitivity — margin compression and weaker operating leverage are likely outcomes. JPMorgan's underweight call therefore implies a view that pass-through will be partial and slower than the market had assumed.

Sector Implications

JPMorgan's downgrade of Essity is not an isolated signal for the tissue and hygiene subsector; it is a lens for broader earnings sensitivity in a market where raw material and energy volatility remain prominent. Peer names in tissue and personal-care manufacturing, especially those with elevated pulp exposure and European production footprints, face comparable margin risk. For investors tracking sector relative performance, a useful comparison is Essity versus non-pulp-intensive consumer staples: the latter have lower direct commodity sensitivity and thus are less likely to face the same scale of near-term margin deterioration (YoY comparisons will show divergence if pulp and power remain elevated).

On pricing dynamics, retailers and distributors will be the transmission mechanism for any cost pass-through. Historically, tissue manufacturers have managed to recover a portion of higher raw-material costs through price increases and product mix optimisation; however, the speed of recovery is variable. Data from prior cycles — notably 2017-2018 and the 2020-2021 pandemic period — shows pass-through can lag raw-cost inflation by quarters, and in some competitive markets never fully offsets the increase. For portfolio managers, the practical implication is to re-evaluate operating leverage assumptions in models and to stress-test scenarios with 200–400 basis point swings in gross margin over 12 months.

Risk Assessment

Key downside risks to Essity's current valuation stem from persistent commodity inflation, currency volatility and demand elasticity. If pulp prices remain elevated through H2 2026, or if energy prices spike in a colder-than-expected winter, operating profit could undershoot consensus by multiple percentage points. Currency exposure — notably SEK/EUR and USD — also matters because input purchases and sales are denominated across currencies; adverse moves can amplify margin impacts. Additionally, a more aggressive retailer pushback on retail price increases could constrain pass-through and amplify volume vs price trade-offs.

Upside risks exist, but they require a faster-than-expected normalisation of pulp or energy prices or successful, rapid pricing actions by manufacturers. For instance, a return of pulp prices toward 2024 levels or a significant decline in European power curves would materially improve gross margins and could prompt a re-appraisal of ratings. Companies with diversified production footprints and long-term pulp contracts would be relatively better placed; therefore, granular assessment of contract exposure and procurement strategy is essential for investors. JPMorgan's downgrade effectively prices in a pessimistic but plausible scenario — one that should be incorporated into sensitivity analysis rather than treated as deterministic.

Fazen Markets Perspective

From a contrarian vantage point, the market's focus on headline pulp and energy moves risks overlooking operational levers Essity can deploy. The company has historically achieved 100–200 basis points of efficiency gains in procurement and logistics during previous cost cycles; if similar structural actions are accelerated — e.g., renegotiated long-term pulp contracts, targeted SKU rationalisation, and energy-efficiency capex — a large portion of the margin gap can be recovered without full commodity normalisation. Moreover, product mix tilt toward higher-margin professional hygiene or consumer-health segments could partially offset tissue headwinds. Investors should therefore parse JPMorgan's call as a signal to interrogate balance-sheet flexibility, procurement cadence and the company's specific pass-through mechanics rather than as a simple 'sell' trigger.

A further non-obvious insight is that downgrades in defensive sectors sometimes create tactical opportunities for long-term holders with clear downside buffers: if consensus overshoots on downside risk and the stress scenario does not materialise, re-rating potential exists as input-price shocks ebb. That said, this is conditional on company execution; the prudent course for institutional allocators is to model multiple scenarios for FY26–FY27 FCF under varying pulp and energy paths and to cross-check management's contract disclosures. For clients seeking deeper sector context, see our coverage on consumer staples and cost inflation dynamics at Fazen Markets and our utilities-and-energy interplay brief at Fazen Markets.

Outlook

Near-term, the priority for market participants is forward guidance from Essity and updated forecasts from large sell-side houses following JPMorgan's call. If Essity revises FY26 margin guidance downward or provides more conservative procurement assumptions, further downgrades and price moves are possible. The calendar suggests Q2 updates and AGM disclosures will be focal points for clarity on contract mix and hedging strategy; investors should watch these events closely for hard data rather than relying solely on index moves.

Over a 12-month horizon, the outlook will hinge on three drivers: the path of pulp prices (index readings), the evolution of European power contracts (Nord Pool and regional exchanges), and Essity's ability to implement margin recovery measures. A scenario analysis is recommended: base case (gradual normalisation, partial pass-through), downside (persistent elevated costs with constrained pass-through), and upside (rapid cost normalisation plus execution gains). For institutional investors, position sizing and covenant stress tests should reflect the probability-weighted outcomes across these scenarios.

Bottom Line

JPMorgan's downgrade of Essity on April 20, 2026 signals credible near-term margin stress from higher pulp and energy costs and warrants a disciplined scenario-based reassessment of forecasts and valuation. Investors should prioritise contract disclosure, procurement strategy and near-term guidance as determinants of downside risk.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.